ArticlePloS one2025
Cl-amidine confers organ protection and improves survival in hemorrhagic shock rats via the PAD4-CitH3-NETs axis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neutrophils and Neutrophil Extracellular Traps in Hepatic Ischemia-Reperfusion Injury: Molecular Mechanisms and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Neutrophil extracellular traps in the tumor microenvironment, metastasis, therapy, and beyond: advances, challenges, and perspectives.Journal of hematology & oncology · 2026Review
- Neutrophils and neutrophil extracellular traps in ischaemia-reperfusion injury: pathophysiological roles and therapeutic potential.Burns & trauma · 2026Review
- High-efficacy serum biomarkers PCSK9 and LCAT predict cognitive impairment in Parkinson's disease.Frontiers in psychology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe occurrence of multi-organ dysfunction following hemorrhagic shock (HS) remains a critical clinical challenge. The excessive formation of neutrophil extracellular trap (NET) Has been identified as a pivotal pathogenic mechanism. This study preliminarily elucidated the protective mechanism of the PAD4 inhibitor Cl-amidine in a rat model of HS.
methodsMale Sprague-Dawley rats were subjected to sublethal (40% blood loss, n = 8) or lethal (50% blood loss, n = 10) HS. Rats were divided into Sham group (catheter placement only), HS group (catheter placement followed by blood withdrawal), Vehicle group (0.9% saline), and Cl-amidine (10 mg/kg in 0.9% saline) groups.
resultsCl-amidine significantly improved the 72-h survival rate and delayed mortality in lethal HS. In Sublethal HS, the drug corrected metabolic disturbances, such as reduced lactate accumulation, while maintaining mean arterial pressure. Mechanistically, the effects of Cl-amidine included reducing circulating cell-free DNA (cf-DNA) and tissue citrullinated histone H3 (CitH3) levels, suppressing PAD4 expression, and improving histopathological outcomes (reduced edema and restored intestinal barrier integrity by upregulation of tight junction proteins Claudin-1/ZO-1). Moreover, Cl-amidine inhibited neutrophil infiltration through ICAM-1 downregulation and reduced the production of TNF-α and IL-6.
conclusionsIn conclusion, Cl-amidine protects against HS by targeting the PAD4-CitH3-NETs axis, breaking the vicious cycle of "NETs-inflammation", restoring barrier integrity, and alleviating multi-organ damage. The synergistic downregulation of ICAM-1 further enhances the therapeutic efficacy, highlighting Cl-amidine as a novel NETs-modulating strategy for HS. This study provides a theoretical and therapeutic foundation for the prevention and treatment of multi-organ injury following HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.